EDWARDS LIFESCIENCES SAS : revenue, balance sheet and financial ratios

EDWARDS LIFESCIENCES SAS is a French company founded 26 years ago, specialized in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques. Based in GUYANCOURT (78280), this company of category ETI shows in 2024 a revenue of 234.3 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - EDWARDS LIFESCIENCES SAS (SIREN 429487507)
Indicator 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Revenue 234 295 415 € 226 130 458 € 212 803 327 € 192 645 197 € 161 907 865 € 151 633 410 € 150 392 112 € 147 901 772 € 135 534 286 € 130 724 507 €
Net income 8 496 713 € 6 532 763 € 5 591 218 € 4 963 639 € 3 848 479 € 4 563 627 € 3 228 173 € 2 675 875 € 2 584 111 € 2 425 538 €
EBITDA 6 974 478 € 10 337 591 € 10 762 864 € 9 539 220 € 7 326 178 € 8 261 669 € 6 128 582 € 5 957 839 € 5 271 530 € 5 160 733 €
Net margin 3.6% 2.9% 2.6% 2.6% 2.4% 3.0% 2.1% 1.8% 1.9% 1.9%

Revenue and income statement

In 2024, EDWARDS LIFESCIENCES SAS achieves revenue of 234.3 M€. Over the period 2015-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +6.7%. Vs 2023: +4%. After deducting consumption (194.5 M€), gross margin stands at 39.8 M€, i.e. a rate of 17%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 7.0 M€, representing 3.0% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 8.5 M€, i.e. 3.6% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2024) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

234 295 415 €

Gross margin (2024) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

39 768 970 €

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

6 974 478 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

5 908 282 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

8 496 713 €

EBITDA margin (2024) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

3.0%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 47%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Cash flow represents 0.8% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

0.0%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

47.406%

Cash flow / Revenue (2024) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

0.82%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

0.0

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

22.2%

Solvency indicators evolution
EDWARDS LIFESCIENCES SAS

Sector positioning

Debt ratio
0.0 2024
2022
2023
2024
Q1: 0.0
Med: 4.27
Q3: 43.96
Excellent

In 2024, the debt ratio of EDWARDS LIFESCIENCES SAS (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.

Financial autonomy
47.41% 2024
2022
2023
2024
Q1: 14.64%
Med: 38.36%
Q3: 60.56%
Good +8 pts over 3 years

In 2024, the financial autonomy of EDWARDS LIFESCIENCES SAS (47.4%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Repayment capacity
0.0 years 2024
2022
2023
2024
Q1: 0.0 years
Med: 0.0 years
Q3: 1.09 years
Excellent -8 pts over 3 years

In 2024, the repayment capacity of EDWARDS LIFESCIENCES SAS (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 197.28. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 6.5x. Operating income very largely covers interest expenses: high safety margin.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

197.284

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

6.47

Liquidity indicators evolution
EDWARDS LIFESCIENCES SAS

Sector positioning

Liquidity ratio
197.28 2024
2022
2023
2024
Q1: 132.74
Med: 202.27
Q3: 325.9
Average +11 pts over 3 years

In 2024, the liquidity ratio of EDWARDS LIFESCIENCES SAS (197.28) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Interest coverage
6.47x 2024
2022
2023
2024
Q1: 0.0x
Med: 0.41x
Q3: 6.25x
Excellent +6 pts over 3 years

In 2024, the interest coverage of EDWARDS LIFESCIENCES SAS (6.5x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 45 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 19 days. The company must finance 26 days of gap between collections and payments. Inventory turnover is 44 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 80 days of revenue, i.e. 51.9 M€ to permanently finance. Over 2015-2024, WCR increased by +273%, requiring additional financing.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

51 936 265 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

45 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

19 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

44 j

WCR in days of revenue (2024) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

80 j

WCR and payment terms evolution
EDWARDS LIFESCIENCES SAS

Positioning of EDWARDS LIFESCIENCES SAS in its sector

Comparison with sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Valuation estimate

Based on 124 transactions of similar company sales (all years), the value of EDWARDS LIFESCIENCES SAS is estimated at 18 820 329 € (range 9 809 427€ - 59 375 453€). With an EBITDA of 6 974 478€, the sector multiple of 0.7x is applied. The price/revenue ratio is 0.21x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
124 transactions
9809k€ 18820k€ 59375k€
18 820 329 € Range: 9 809 427€ - 59 375 453€
NAF 5 all-time

Valuation detail by method

Ajustez les pondérations selon votre analyse

EBITDA Multiple 50%
6 974 478 € × 0.7x
Estimation 4 909 231 €
2 320 769€ - 17 867 811€
Revenue Multiple 30%
234 295 415 € × 0.21x
Estimation 49 898 926 €
27 059 005€ - 151 144 666€
Net Income Multiple 20%
8 496 713 € × 0.8x
Estimation 6 980 183 €
2 656 708€ - 25 490 742€

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 124 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de gros (commerce interentreprises) de produits pharmaceutiques)

Compare EDWARDS LIFESCIENCES SAS with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Frequently asked questions about EDWARDS LIFESCIENCES SAS

What is the revenue of EDWARDS LIFESCIENCES SAS ?

The revenue of EDWARDS LIFESCIENCES SAS in 2024 is 234.3 M€.

Is EDWARDS LIFESCIENCES SAS profitable?

Yes, EDWARDS LIFESCIENCES SAS generated a net profit of 8.5 M€ in 2024.

Where is the headquarters of EDWARDS LIFESCIENCES SAS ?

The headquarters of EDWARDS LIFESCIENCES SAS is located in GUYANCOURT (78280), in the department Yvelines.

Where to find the tax return of EDWARDS LIFESCIENCES SAS ?

The tax return of EDWARDS LIFESCIENCES SAS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does EDWARDS LIFESCIENCES SAS operate?

EDWARDS LIFESCIENCES SAS operates in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques (NAF code 46.46Z). See the 'Sector positioning' section above to compare the company with its competitors.